Machet L, Vaillant L, Bensaid P, Muller C, Lorette G
Service de Dermatologie, CHU Trousseau, Tours.
Ann Dermatol Venereol. 1992;119(10):737-43.
Eight patients, six men and two women, had chronic photosensitivity of 2.0 +/- 1.1 years' duration. The clinical and photobiological signs were consistent with a diagnosis of chronic actinic dermatitis syndrome. Photosensitivity was extremely severe, and the minimal erythematous dose (MED) in polychromatic light was dramatically decreased in all eight patients (82 +/- 20 mJ/cm2; range: 25-200 for a normal MED range of 1.000 to 2.000 mJ/cm2). Photopatchtests were positive to phenothiazine in four patients, to fragrance mix and oxybenzone in two patients, to balsam of Peru and musk ambrette in one patient each. Seven patients were treated with corticopuvatherapy. They all were markedly improved after one month of treatment, recovering normal MED and outdoor activities. Corticosteroid therapy was gradually reduced and stopped after 3 months, while puvatherapy was continued for several months. Treatment was withdrawn in three patients. The minimal erythematous dose was monitored after discontinuation of therapy: a progressive decrease of MED was observed, accompanied by a relapse in two of the three patients. This relapse was well controlled by another course of corticopuvatherapy. Four other patients had, after discontinuation of treatment, another course of corticopuvatherapy reinstituted in the early spring. Puvatherapy was stopped at the end of october. One patient did not receive corticopuvatherapy because she was living far from a puvatherapy centre. She was treated with azathioprine for 6 months without improvement, then with azathioprine+prednisolone 20 mg daily during 2 years with slight improvement. Corticopuvatherapy is a very efficient means of treating severe chronic actinic dermatitis.(ABSTRACT TRUNCATED AT 250 WORDS)
8名患者,6名男性和2名女性,患有持续时间为2.0±1.1年的慢性光敏性。临床和光生物学体征与慢性光化性皮炎综合征的诊断相符。光敏性极为严重,所有8名患者在多色光下的最小红斑剂量(MED)均显著降低(82±20 mJ/cm²;正常MED范围为1000至2000 mJ/cm²时,其范围为25 - 200)。光斑贴试验中,4名患者对吩噻嗪呈阳性,2名患者对香料混合物和氧苯酮呈阳性,1名患者分别对秘鲁香脂和葵子麝香呈阳性。7名患者接受了皮质类固醇光化学疗法。治疗1个月后他们均有明显改善,恢复了正常的MED并能进行户外活动。3个月后皮质类固醇疗法逐渐减量并停止,而光化学疗法持续了数月。3名患者停止了治疗。治疗中断后监测最小红斑剂量:观察到MED逐渐降低,3名患者中有2名复发。再次进行皮质类固醇光化学疗法很好地控制了这种复发。另外4名患者在停止治疗后,于早春再次进行了皮质类固醇光化学疗法。10月底停止光化学疗法。1名患者未接受皮质类固醇光化学疗法,因为她住得离光化学疗法中心很远。她接受了6个月的硫唑嘌呤治疗但无改善,然后在2年期间每天服用硫唑嘌呤 + 20 mg泼尼松龙,稍有改善。皮质类固醇光化学疗法是治疗严重慢性光化性皮炎的一种非常有效的方法。(摘要截短至250字)